Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vivesto AB is a Swedish pharmaceutical company focused on developing a new generation of drugs in human and veterinary oncology. The company’s primary purpose is to create treatment options for cancers that are difficult to treat, addressing unmet medical needs in both human patients and companion animals. Vivesto AB concentrates on research and development activities, leveraging formulation technologies and oncology expertise to enhance the delivery and effectiveness of established and novel anticancer agents. Its portfolio targets a range of solid tumors and hematologic malignancies, positioning the company within the specialized segment of oncology therapeutics. In the veterinary field, Vivesto AB develops cancer treatments tailored to the specific medical and regulatory requirements of animal health. Headquartered in Sweden, Vivesto AB collaborates with industry partners, contract manufacturers, and clinical research organizations to advance its pipeline from preclinical development through clinical studies, aiming to supply hospitals, specialty clinics, and veterinary practices in key global markets.
kr 0.73
kr 0.03 (-3.46%)
EOD Jun 26, 2026 · Twelve Data
Negative free cash flow of -kr 44M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 33M
▲ +14.3% YoY
Op. Margin
—
ROIC
-18.36%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 36M
▲ +7.3% YoY
Op. Cash Flow (TTM)
-kr 25M
▲ +23.3% YoY
Net Debt
kr 11M
Cash & Equiv.
kr 2M
Continue Research
Vivesto AB (VIVE.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Vivesto AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Vivesto AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -18.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh VIVE.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.